Literature DB >> 35513591

Hepatocellular Carcinoma Recurrence Risk in the Context of Emerging Therapies.

Mark A Healy1, Michael A Choti2.   

Abstract

Entities:  

Year:  2022        PMID： 35513591     DOI： 10.1245/s10434-022-11709-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  2 in total

1.  Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular carcinoma.

Authors:  Weiyu Hu; Xufeng Pang; Weidong Guo; Liqun Wu; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Correction to: Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Authors:  Lan-Qing Yao; Zheng-Liang Chen; Zi-Han Feng; Yong-Kang Diao; Chao Li; Hai-Ying Sun; Jian-Hong Zhong; Ting-Hao Chen; Wei-Min Gu; Ya-Hao Zhou; Wan-Guang Zhang; Hong Wang; Yong-Yi Zeng; Han Wu; Ming-Da Wang; Xin-Fei Xu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Ann Surg Oncol       Date:  2022-08       Impact factor: 5.344
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.